A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

NCT00931463 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

558

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: raltegravir
DRUG: 2N(t)RTI
DRUG: Ritonavir-boosted lopinavir

Sponsor

Kirby Institute

Collaborators

[object Object]
[object Object]
[object Object]